---
id: cystic-fibrosis-exacerbation_278
category: clinical-syndromes
tags: [cystic-fibrosis, pulmonary-exacerbation, Pseudomonas, MRSA, Burkholderia]
deck: Infectious Diseases
created: 2025-01-11
modified: 2025-01-11
---

## Cystic Fibrosis: Pulmonary Exacerbation Pathogens and Treatment

**Q:** What are the key pathogens causing CF pulmonary exacerbations, and how are they treated?

**A:**

**Key Pathogens (age-dependent progression):**

| Pathogen | Prevalence | Clinical Impact |
|----------|------------|-----------------|
| ***Staphylococcus aureus*** (MSSA/MRSA) | MRSA: >25% (↑ over last decade) | MRSA → ↑ lung function decline, ↓ survival, failure to recover post-exacerbation |
| ***Pseudomonas aeruginosa*** | Most common chronic pathogen | Biofilm formation, mucoid strains, MDR common |
| **Burkholderia cepacia complex** | Varies | **Poor prognosis**, extreme antibiotic resistance, risk of "cepacia syndrome" (rapid decline) |
| *H. influenzae* | Early childhood | Usually resolves with age |
| *Stenotrophomonas maltophilia, Achromobacter* | Emerging | Often MDR |

**Treatment of Pulmonary Exacerbation:**

**General Approach:**
- **Combination IV antibiotics** × 14 days (guided by susceptibility testing)
- Aggressive airway clearance, nutritional support

**Empiric Regimens (adjust per culture):**

| Target | Regimen |
|--------|---------|
| ***P. aeruginosa*** | **Ceftazidime 2 g IV q8h** (or piperacillin-tazobactam) + **tobramycin 10 mg/kg IV q24h** (or amikacin) |
| **MRSA** | Add **vancomycin 15-20 mg/kg IV q8-12h** (target trough 15-20) OR **linezolid 600 mg IV/PO q12h** |
| **Burkholderia** | Often requires **≥3 drugs** (e.g., meropenem + TMP-SMX + minocycline) based on susceptibilities |

**Poor Prognosis Predictors:**
- MRSA, Burkholderia, MDR *P. aeruginosa*

**Pearl:** CFTR modulators reduce bacterial burden but rarely achieve eradication.

**Media:**

**Sources:** [Ann ATS Antibiotic Management CF], [ERR Treatment Pulm Exacerbations CF], [EMCrit IBCC CF Pulmonary Exacerbation], [Cochrane Burkholderia Treatment]
